Results 101 to 110 of about 80,955 (206)

The ENST00000539930 transcript predicts sensitivity to PARP inhibitors and clinical prognosis in cancers

Oncologie
Synthetic lethality-based cancer therapy, particularly using PARP inhibitors, faces resistance challenges. This study aims to explore the role of gene-specific transcripts due to alternative splicing in PARP inhibitor resistance.
Xu Chi, Li Cong, Wang Wenna, Li Yiqun, Wang Ting, Sun Fangzhou, Yang Xiaoqi, Li Chunxiao, Ma Fei   +8 more
doaj   +1 more source

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

, 2020
© 2017 The Author(s) PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of BET bromodomain inhibition with PARP inhibition in
Speicher D., Bitler B., Zhao B., Yokoyama Y., Kossenkov A., Khabele D., Zhang R., Simpkins F., Fatkhutdinov N., Zhu H., Karakashev S., Wilson A.   +11 more
core  

Discovery of Stereospecific PARP‑1 Inhibitor Isoindolinone NMS-P515

, 2019
Poly­(ADP-ribose) polymerase-1 (PARP-1) is an enzyme involved in signaling and repair of DNA single strand breaks. PARP-1 employs NAD+ to modify substrate proteins via the attachment of poly­(ADP-ribose) chains.
Viviana Desperati (6469613), Alessia Montagnoli (1533301), Alessandra Cirla (1533322), Elena Casale (1533292), Helena Posteri (1533316), Federico Riccardi-Sirtori (1533313), Alessandra Scolaro (1533328), Eduard R. Felder (1911142), Paolo Orsini (1533286), Daniela Borghi (1533331), Marina Ciomei (1533355), Antonella Isacchi (75227), Gianluca Papeo (1533361), Sonia Rainoldi (1533343), Daniele Donati (1533319), Marco Guanci (6469616), Arturo Galvani (1533352), Nilla R. Avanzi (6469610)   +17 more
core   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Tryfonopoulos, Dimitrios, Eustace, Alexander J., Mahgoub, Thamir, O\u27Donovan, Norma, Crown, John, O'Donovan, Norma   +5 more
core  

PARP Inhibitors in Ovarian Cancer [PDF]

New England Journal of Medicine, 2020
Ian E, Haines, George L, Gabor Miklos
openaire   +4 more sources

Imaging Pharmacodynamics of a PARP Inhibitor

Radiology: Imaging Cancer, 2021
openaire   +2 more sources

[18F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology

Including poly(ADP-ribose) polymerase (PARP) inhibitors in managing patients with inoperable tumors has significantly improved outcomes. The PARP inhibitors hamper single-strand deoxyribonucleic acid (DNA) repair by trapping poly(ADP-ribose)polymerase ...
Akram Al-Ibraheem, Mike M. Sathekge, Sipho Mdanda, Honest Ndlovu, Kgomotso M. G. Mokoala, Mankgopo M. Kgatle, Ismaheel O. Lawal   +6 more
core   +1 more source

Radiosensitization Effect of PARP Inhibitor in Cells Exposed to Low and High LET Radiation

, 2011
Purpose: To improve radiotherapy of cancer patients, development of efficient radiosensitizer is one of the most important issues in clinical cancer treatment.
694155, 694147, 694146, 益谷 美都子, 694149, 白井 秀徳, 694148, 平井 崇久, Shirai, Hidenori, Masutani, Mitsuko, 笹井 啓資, 岡安 隆一, Hirai, Takahisa, Okayasu, Ryuichi, 694150, 694152, 694151, 694154, Sasai, Keisuke, 694153   +19 more
core  

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. [PDF]

Biomedicines
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP.   +11 more
europepmc   +1 more source

Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lewis GJ, Jewell RC, Krishnatry AS, Taskar KS.   +3 more
europepmc   +1 more source